These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9555 related articles for article (PubMed ID: 1610965)

  • 1. Cutaneous melanoma at Lawrence Livermore National Laboratory: comparison with rates in two San Francisco bay area counties.
    Gong G; Whittemore AS; West D; Moore DH
    Cancer Causes Control; 1992 May; 3(3):191-7. PubMed ID: 1610965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance bias and the excess risk of malignant melanoma among employees of the Lawrence Livermore National Laboratory.
    Hiatt RA; Krieger N; Sagebiel RW; Clark WH; Mihm MC
    Epidemiology; 1993 Jan; 4(1):43-7. PubMed ID: 8420580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The possible effect of increased surveillance on the incidence of malignant melanoma.
    Hiatt RA; Fireman B
    Prev Med; 1986 Nov; 15(6):652-60. PubMed ID: 3797396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant melanoma among employees of Lawrence Livermore National Laboratory.
    Austin DF; Reynolds PJ; Snyder MA; Biggs MW; Stubbs HA
    Lancet; 1981 Oct; 2(8249):712-6. PubMed ID: 6116857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer incidence rates among Lawrence Livermore National Laboratory (LLNL) employees: 1974-1997.
    Whorton MD; Moore DN; Seward JP; Noonan KA; Mendelsohn ML
    Am J Ind Med; 2004 Jan; 45(1):24-33. PubMed ID: 14691966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal trends in the incidence of cutaneous malignant melanoma among Caucasians in the San Francisco-Oakland MSA.
    Horn-Ross PL; Holly EA; Brown SR; Aston DA
    Cancer Causes Control; 1991 Sep; 2(5):299-305. PubMed ID: 1932542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer incidence among employees of the Lawrence Livermore National Laboratory, 1969-1980.
    Reynolds P; Austin DF
    West J Med; 1985 Feb; 142(2):214-8. PubMed ID: 4013251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case-control study of malignant melanoma among employees of the Lawrence Livermore National Laboratory.
    Moore DH; Patterson HW; Hatch F; Discher D; Schneider JS; Bennett D; Mendelsohn ML
    Am J Ind Med; 1997 Oct; 32(4):377-91. PubMed ID: 9258392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early diagnosis of cutaneous malignant melanoma at Lawrence Livermore National Laboratory.
    Schneider JS; Moore DH; Sagebiel RW
    Arch Dermatol; 1990 Jun; 126(6):767-9. PubMed ID: 2346320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening program reduced melanoma mortality at the Lawrence Livermore National Laboratory, 1984 to 1996.
    Schneider JS; Moore DH; Mendelsohn ML
    J Am Acad Dermatol; 2008 May; 58(5):741-9. PubMed ID: 18068264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of an excess of melanoma among employees of the Lawrence Livermore National Laboratory.
    Austin DF; Reynolds P
    Am J Epidemiol; 1997 Mar; 145(6):524-31. PubMed ID: 9063342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant melanoma incidence at the Los Alamos National Laboratory.
    Acquavella JF; Tietjen GL; Wilkinson GS; Key CR; Voelz GL
    Lancet; 1982 Apr; 1(8277):883-4. PubMed ID: 6122103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying individuals at high risk of melanoma: a practical predictor of absolute risk.
    Fears TR; Guerry D; Pfeiffer RM; Sagebiel RW; Elder DE; Halpern A; Holly EA; Hartge P; Tucker MA
    J Clin Oncol; 2006 Aug; 24(22):3590-6. PubMed ID: 16728488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of malignant melanoma in central Europe: risk factors and prognostic predictors. Results of the Central Malignant Melanoma Registry of the German Dermatological Society.
    Garbe C; Orfanos CE
    Pigment Cell Res; 1992; Suppl 2():285-94. PubMed ID: 1409431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical surveillance for melanoma at the Lawrence Livermore National Laboratory.
    Wald PH; Schneider JS
    Occup Med; 1990; 5(3):607-16. PubMed ID: 2218804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous malignant melanoma in Australia, 1989.
    Jelfs PL; Giles G; Shugg D; Coates M; Durling G; Fitzgerald P; Ring I
    Med J Aust; 1994 Aug; 161(3):182-7. PubMed ID: 8035720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States, 1999-2006.
    Wu XC; Eide MJ; King J; Saraiya M; Huang Y; Wiggins C; Barnholtz-Sloan JS; Martin N; Cokkinides V; Miller J; Patel P; Ekwueme DU; Kim J
    J Am Acad Dermatol; 2011 Nov; 65(5 Suppl 1):S26-37. PubMed ID: 22018064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The German melanoma registry and environmental risk factors implied.
    Garbe C; Weiss J; Krüger S; Garbe E; Büttner P; Bertz J; Hoffmeister H; Guggenmoos-Holzmann I; Jung EG; Orfanos CE
    Recent Results Cancer Res; 1993; 128():69-89. PubMed ID: 8356335
    [No Abstract]   [Full Text] [Related]  

  • 19. Regional differences in known risk factors and the higher incidence of breast cancer in San Francisco.
    Robbins AS; Brescianini S; Kelsey JL
    J Natl Cancer Inst; 1997 Jul; 89(13):960-5. PubMed ID: 9214676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma in a cohort of organ transplant recipients: Experience from a dedicated transplant dermatology clinic in Victoria, Australia.
    Maor D; Vajdic CM; Cumming S; Fahey V; Bala HR; Snaidr V; Brennand S; Goh MSY; Chong AH
    J Am Acad Dermatol; 2020 Sep; 83(3):773-779. PubMed ID: 31706934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 478.